Schubert GE, Pavkovic MB, Bethke-Bedurftig BA (1982) Tubular urachal remnants in adult bladders. J Urol 127(1):40–42
2.Amin MB, Smith SC, Eble JN, Rao P, Choi WWL, Tamboli P, Young RH (2014) Glandular neoplasms of the urachus: a report of 55 cases emphasizing mucinous cystic tumors with proposed classification. Am J Surg Pathol 38(8):1033–1045. https://doi.org/10.1097/PAS.0000000000000250
3.Kumar N, Khosla D, Kumar R, Mandal AK, Saikia UN, Kapoor R, Singh SK, Sharma SC (2014) Urachal carcinoma: clinicopathological features, treatment and outcome. J Cancer Res Ther 10(3):571–574. https://doi.org/10.4103/0973-1482.137955
4.Reis H, Krafft U, Niedworok C, Módos O, Herold T, Behrendt M, al-Ahmadie H, Hadaschik B, Nyirady P, Szarvas T (2018) Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. Dis Markers:7308168. https://doi.org/10.1155/2018/7308168
5.Szarvas T, Modos O, Niedworok C et al (2016) Clinical, prognostic, and therapeutic aspects of urachal carcinoma-a comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 34(9):388–398. https://doi.org/10.1016/j.urolonc.2016.04.012
6.Riva G, Mian C, Luchini C, Girolami I, Ghimenton C, Cima L, Novelli L, Hanspeter E, Mazzoleni G, Schwienbacher C, Pycha S, D’Elia C, Trenti E, Pycha A, Martignoni G, Hes O, Eccher A, Nesi G, Brunelli M (2019) Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis. Virchows Arch 474(1):13–20. https://doi.org/10.1007/s00428-018-2467-1
7.Reis H, van der Vos KE, Niedworok C, Herold T, Módos O, Szendrői A, Hager T, Ingenwerth M, Vis DJ, Behrendt MA, de Jong J, van der Heijden MS, Peyronnet B, Mathieu R, Wiesweg M, Ablat J, Okon K, Tolkach Y, Keresztes D, Nagy N, Bremmer F, Gaisa NT, Chlosta P, Kriegsmann J, Kovalszky I, Timar J, Kristiansen G, Radzun HJ, Knüchel R, Schuler M, Black PC, Rübben H, Hadaschik BA, Schmid KW, van Rhijn BWG, Nyirády P, Szarvas T (2018) Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. Int J Cancer 143:1764–1773. https://doi.org/10.1002/ijc.31547
CAS Article PubMed Google Scholar
8.Modos O, Reis H, Niedworok C et al (2016) Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance. Oncotarget 7(26):39293–39301. https://doi.org/10.18632/oncotarget.9828
Article PubMed PubMed Central Google Scholar
9.Kardos J, Wobker SE, Woods ME, Nielsen ME, Smith AB, Wallen EM, Pruthi RS, Hayward MC, McGinty KA, Grilley-Olson JE, Patel NM, Weck KE, Black P, Parker JS, Milowsky MI, Hayes DN, Kim WY (2017) Comprehensive molecular characterization of Urachal adenocarcinoma reveals commonalities with colorectal Cancer, including a Hypermutable phenotype. JCO Prec Oncol 1(1):1–12. https://doi.org/10.1200/po.17.00027
10.Lee S, Lee J, Sim SH, Lee Y, Moon KC, Lee C, Park WY, Kim NKD, Lee SH, Lee H (2017) Comprehensive somatic genome alterations of urachal carcinoma. J Med Genet 54(8):572–578. https://doi.org/10.1136/jmedgenet-2016-104390
CAS Article PubMed Google Scholar
11.Hang JF, Pan CC (2017) Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. Pathology. 49(3):316–317. https://doi.org/10.1016/j.pathol.2016.11.017
CAS Article PubMed Google Scholar
12.Sirintrapun SJ, Ward M, Woo J, Cimic A (2014) High-stage urachal adenocarcinoma can be associated with microsatellite instability and KRAS mutations. Hum Pathol 45(2):327–330. https://doi.org/10.1016/j.humpath.2013.09.008
CAS Article PubMed Google Scholar
13.Loh KP, Mondo E, Hansen EA, Sievert L, Fung C, Sahasrabudhe DM, Guancial E (2016) Targeted therapy based on tumor genomic analyses in metastatic Urachal carcinoma. Clin Genitourin Cancer 14(4):e449–e452. https://doi.org/10.1016/j.clgc.2016.03.013
14.Collazo-Lorduy A, Castillo-Martin M, Wang L, Patel V, Iyer G, Jordan E, al-Ahmadie H, Leonard I, Oh WK, Zhu J, McBride RB, Cordon-Cardo C, Solit DB, Sfakianos JP, Galsky MD (2016) Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. Eur Urol 70(5):771–775. https://doi.org/10.1016/j.eururo.2016.04.037
Article PubMed PubMed Central Google Scholar
15.Cha S, Lee J, Shin JY, Kim JY, Sim SH, Keam B, Kim TM, Kim DW, Heo DS, Lee SH, Kim JI (2016) Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer 16:170. https://doi.org/10.1186/s12885-016-2209-1
CAS Article PubMed PubMed Central Google Scholar
16.Singh H, Liu Y, Xiao X et al (2016) Whole exome sequencing of urachal adenocarcinoma reveals recurrent NF1 mutations. Oncotarget 7(20):29211–29215. https://doi.org/10.18632/oncotarget.8640
Article PubMed PubMed Central Google Scholar
17.Cancer Genome Atlas N (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407):330–337. https://doi.org/10.1038/nature11252
18.Cornejo KM, Paner GP, Tomaszewicz K et al (2016) Mutational profile using next generation sequencing may aid in distinguishing Urachal adenocarcinoma from bladder adenocarcinoma nature modern pathology, 105th annual meeting of the United States and Canadian academy of pathology (USCAP), 2015, Seattle. Washington. 29:528–556. https://doi.org/10.1038/modpathol.2016.25
19.Roy S, Smith MA, Cieply KM, Acquafondata MB, Parwani AV (2012) Primary bladder adenocarcinoma versus metastatic colorectal adenocarcinoma: a persisting diagnostic challenge. Diagn Pathol 7:151. https://doi.org/10.1186/1746-1596-7-151
Article PubMed PubMed Central Google Scholar
20.Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 120(19):3327–3335. https://doi.org/10.1242/jcs.03485
CAS Article PubMed Google Scholar
21.Yazdani Y, Farazmandfar T, Azadeh H, Zekavatian Z (2016) The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci 23:9. https://doi.org/10.1186/s12929-016-0228-5
CAS Article PubMed PubMed Central Google Scholar
22.Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97(8):1139–1145. https://doi.org/10.1038/sj.bjc.6604009
CAS Article PubMed PubMed Central Google Scholar
23.Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE (1984) Malignant urachal lesions. J Urol 131(1):1–8
24.Toubaji A, Jordan EJ, Desai N et al (2016) Genomic Alterations in Primary Bladder Adenocarcinoma and Urachal Adenocarcinoma. Nature Modern Pathology, 106th Annual Meeting of the United States and Canadian Academy of Pathology (USCAP), 2016, San Antonio, Texas. 30:539. https://doi.org/10.1038/modpathol.2016.265
25.Pires-Luis A, Martinek P, Filipovic J et al (2018) Primary adenocarcinoma of the urinary bladder: next-generation sequencing (NGS) of non-urachal enteric-type adenocarcinomas, Urachal adenocarcinomas, mucinous adenocarcinomas, and colonic Metaplasias/adenomas. Drugs Future 43:359. https://doi.org/10.1358/dof.2018.043.05.2808557
26.Lee B, Jordan E, Won H, Bagrodia A, Desai N, Bajorin D, Rosenberg J, Bochner B, Kim W, Berger M, Solit D, al-Ahmadie H, Iyer G (2016) Mutational landscape of primary bladder and Urachal adenocarcinoma. J Urol 195(4S):e1133–e11e4. https://doi.org/10.1016/j.juro.2016.02.2431
27.Wong SZ, Lo E, Lee K et al (2004) Prognostic and diagnostic significance of ß-catenin nuclear Immunostaining in colorectal Cancer. Clin Cancer Res 10(4):1401–1408. https://doi.org/10.1158/1078-0432.CCR-0157-03
CAS Article PubMed Google Scholar
28.Alomar SY, Mansour L, Abuderman A, Alkhuriji A, Arafah M, Alwasel S, Harrath AH, Almutairi M, Trayhyrn P, Dar JA (2016) β-Catenin accumulation and S33F mutation of CTNNB1 gene in colorectal cancer in Saudi Arabia. Pol J Pathol 67(2):156–162. https://doi.org/10.5114/pjp.2016.61452
CAS Article PubMed Google Scholar
29.Perrone F, Lampis A, Orsenigo M, di Bartolomeo M, Gevorgyan A, Losa M, Frattini M, Riva C, Andreola S, Bajetta E, Bertario L, Leo E, Pierotti MA, Pilotti S (2009) PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol 20(1):84–90. https://doi.org/10.1093/annonc/mdn541
留言 (0)